이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

CD34 선택을 통한 동원된 말초 혈액 줄기 세포의 생체 외 T 세포 고갈 (EXCESS)

2026년 11월 11일 업데이트: Robert Krance, Baylor College of Medicine

CD34 선택(EXCESS)을 통한 동원된 말초 혈액 줄기 세포의 Ex Vivo T 세포 고갈

Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) for the participant and his or her disease does not permit enough time to identify another donor (like someone from a registry list that is not his or her relative) or another suitable donor has not been identified. However, a close relative of the patient has been identified whose stem cells are not a perfect match, but can be used.

Alternatively, the patient may have already received a stem cell transplant but have evidence of mixed chimerism, which means some of the patient's own bone marrow cells are present, rather than all of the donor's cells. This may lead to an increased risk of the disease coming back. Or, the patient may have all donor cells but his or her bone marrow is not working very well, which may lead to frequent blood or platelet (cells that help in clotting blood) transfusions or infection.

Regardless of the reason, it may be necessary to isolate stem cells from a haploidentical (half-match) donor in order to provide bone marrow function. Because the stem cells from the donor are only half-matched to the participant, the risk of graft-versus-host disease (GvHD) is very high. GvHD is a complication after transplant caused by donor T cells (graft) that attack the transplant recipient, and this complication can cause death after transplant. Thus, it is important that the donor's blood cells are treated to minimize cells that are most likely to attack the host's tissues. This is done by using a special device to capture the CD34+ stem cells from the donor's stem cell product prior to giving the cells to the host. This method minimizes the donor T cells, which are responsible for causing GvHD.

Purpose: In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, investigators would like to specially treat the donor's blood cells to minimize the cells that are most likely to attack the patient's tissues.

연구 개요

상세 설명

Participation in this project will last approximately one year with follow-up exams.

Before treatment can begin, stem cells will be collected from the donor (a close relative) that has been selected as the best match for the participant. White blood cells will be collected from the donor. The cells will then be mixed with a special protein, called a CD34 antibody, that binds to the stem cells, which will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory. This is an investigational device that is not approved by the FDA. Although this device is not approved for use in this country, it has been in use for years and is approved in other countries. The stem cells will be collected and given fresh or they can be frozen before they will be given to the participant.

On about days 28, 60, 100, 180 and 365 after the transplant, the participant will have the same tests/evaluations since the time of transplant. For patients who do not develop GvHD, they are not required to have these tests/evaluations.

In addition, for purposes of the study, health-related information will be collected for a year from the time of stem cell infusion. This will be used to determine survival, relapse, infections and GvHD that may occur following transplant.

연구 유형

중재적

등록 (추정된)

241

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Marlen Dinu
  • 전화번호: 832-824-4881
  • 이메일: mxdinu@txch.org

연구 연락처 백업

연구 장소

    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • Houston Methodist Hospital
        • 연락하다:
        • 연락하다:
      • Houston, Texas, 미국, 77030
        • 모병
        • Texas Children's Hospital
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

70년 이하 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

  1. Patient requiring allogeneic SCT
  2. Age between birth and 70 years
  3. Patient and/or responsible person able to understand and sign consent

Exclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
  4. Cardiac dysfunction (LVSF less than 25%)
  5. Psychiatric disturbance
  6. Lansky or Karnofsky score < 50%
  7. The presence of severe hepatic disease (direct bilirubin >3x upper limit of normal and AST > 5x upper limit of normal).
  8. Creatinine > 3x normal
  9. Known HIV Positivity
  10. Pregnancy

Inclusion Criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

  1. Allogeneic SCT Recipient requiring additional cellular therapy

  2. Age between birth and 70 years

  3. Patient and/or responsible person able to understand and sign consent

  4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:

    1. Evidence of mixed chimerisms (less than 95% donor cells)
    2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
    3. Relapsed or persistent disease

Exclusion criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Known HIV positivity
  4. Pregnancy

Inclusion Criteria for CD34+ Topoff WITH conditioning (COHORT 3)

  1. Allogeneic SCT Recipient requiring additional cellular therapy

  2. Age between birth and 70 years

  3. Patient and/or responsible person able to understand and sign consent

  4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:

    1. Evidence of mixed chimerisms (less than 95% donor cells)
    2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
    3. Relapsed or persistent disease

Exclusion criteria for CD34+ Topoff WITH Conditioning (COHORT 3)

  1. Active, acute GVHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Pulmonary disfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
  4. Cardiac dysfunction (LVSF less than 25%)
  5. Psychiatric disturbance
  6. Lansky or Karnofsky score < 50%
  7. The presence of severe hepatic disease (direct bilirubin > 3x upper limit of normal and AST > 5x upper limit of normal)
  8. Creatinine > 3x normal
  9. Known HIV positivity
  10. Pregnancy

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 2: CD34+ cells as a top off Without Conditioning

Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a "topoff" without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

실험적: Cohort 1: CD34+ Cells for transplant

Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

실험적: Cohort 3: CD34+ cells as a top off With Conditioning

Cohort 3 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD 34+ Reagent System' as a "topoff" with the need for additional conditioning prior to the infusion. These patients who have already received SCT with conditioning and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
For Cohort 1: the rate of primary engraftment 50 days post SCT
기간: 50 days

Primary engraftment is defined as achievement of absolute neutrophil count (ANC) is greater than or equal to 500/ul for three consecutive days by day 50 post transplant. The treatment regimen will be considered clinically useful if the primary engraftment rate is at least 85%.

50 days
For Cohort 2 (Without Conditioning) and Cohort 3 (With Conditioning): The total incidence of overall acute GvHD (greater than or equal to grade 3)
기간: 100 days

The overall incidence of acute GvHD will be measured 100 days post stem cell transplant. The regimen will be considered acceptable if aGvHD greater than or equal to grade 3 rate is at least 10% or lower.

100 days

2차 결과 측정

결과 측정
측정값 설명
기간
Assessment of Long Term Survival
기간: 1 year

Long term survival of recipients of G-CSF mobilized peripheral blood stem cells depleted of T cells by positive selection for the CD34+ antigen

1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Robert Krance, MD, Baylor College of Medicine

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2010년 10월 1일

기본 완료 (추정된)

2027년 10월 1일

연구 완료 (추정된)

2027년 11월 1일

연구 등록 날짜

최초 제출

2010년 8월 25일

QC 기준을 충족하는 최초 제출

2010년 8월 25일

처음 게시됨 (추정된)

2010년 8월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • H-27251 EXCESS
  • EXCESS (기타 식별자: Baylor College of Medicine)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다